Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF-3 nasal dry powder challenge study in healthy adults experimentally infected with influenza A
2015-001103-31Phase 2Completed
- Sponsor
- Autoimmune Technologies LLC
- Start
- May 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Influenza A infection comparing FF-3 with Placebo (2 arms). Primary endpoint: Co-primary endpoints. Started May 2015; status: completed.
02
Drugs
flufirvitide
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on 2015-001103-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001103-31.